Medicsight

Medicsight was a medical technology company that specialized in the development of Computer-Aided Detection (CAD) software for the early detection of cancer. The company's core technology utilized advanced image analysis algorithms to assist radiologists in identifying potential abnormalities, such as colorectal polyps and lung nodules, in CT scans. Its flagship products, Medicsight Colon CAD and Medicsight Lung CAD, received significant regulatory clearances, including FDA 510(k) and CE marking. These tools were designed to enhance diagnostic accuracy and streamline the workflow for medical imaging professionals globally. Following its acquisition and integration into MGT Capital Investments, the company's focus shifted away from medical imaging.